Women's Health: Numbers Too Big To Ignore
This article was originally published in Start Up
Executive Summary
The women's health opportunity in the US is $2.75 billion on an annual basis, and it's growing at a compounded rate of 16% per year. Looking forward, demographics, the aging of the population, and technological innovations will continue to fuel growth. New technologies promise to cause one particular category in women's health to blossom; the treatment of uterine fibroids. According to "Women's Health: US Markets for Benign Uterine Condition Management Products," a report recently published by the Medtech Insight division of Windhover Information Inc., the number of fibroid treatments is expected to increase at a compound annual rate of 21.3%. The report also discusses the markets for the treatment of menorrhagia and endometriosis.
You may also be interested in...
Cytyc Together with Hologic: There's a Certain Logic
What do you get when you cross a women's health company that sells screening and diagnostic imaging technologies to hospitals and radiologists, with a women's health company that sells diagnostics and therapeutic devices to Ob-Gyns? A single company capable of selling goods and services across the entire continuum of care, according to Rob Cascella, president & COO of Hologic, who thus revealed the reasoning behind the $6.5 billion proposed merger of Hologic with Cytyc.
Mirabilis Medica Inc.
The outstanding success of Novacept, the developer of a device that enabled an office-based procedure for endometrial ablation, demonstrates that Ob-Gyns are eager to offer minimally-invasive, safe, and rapid procedures to their patients as an alternative to the two extremes of surgically removing the uterus or doing nothing. Now Mirabilis Medical, headed up by a Novacept co-founder, hopes to accomplish the same thing for uterine fibroids.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”